CA3226178A1 - Gdf15 fusion proteins and uses thereof - Google Patents
Gdf15 fusion proteins and uses thereof Download PDFInfo
- Publication number
- CA3226178A1 CA3226178A1 CA3226178A CA3226178A CA3226178A1 CA 3226178 A1 CA3226178 A1 CA 3226178A1 CA 3226178 A CA3226178 A CA 3226178A CA 3226178 A CA3226178 A CA 3226178A CA 3226178 A1 CA3226178 A1 CA 3226178A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- fusion protein
- gdf15
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110977378.7 | 2021-08-24 | ||
| CN202110977378 | 2021-08-24 | ||
| PCT/CN2022/114096 WO2023025120A1 (en) | 2021-08-24 | 2022-08-23 | Gdf15 fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226178A1 true CA3226178A1 (en) | 2023-03-02 |
Family
ID=85321545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226178A Pending CA3226178A1 (en) | 2021-08-24 | 2022-08-23 | Gdf15 fusion proteins and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20240350588A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4393941A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532882A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240049337A (cg-RX-API-DMAC7.html) |
| CN (3) | CN115925982A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022333099A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226178A1 (cg-RX-API-DMAC7.html) |
| WO (3) | WO2023025120A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101374454B1 (ko) * | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| JP2013537416A (ja) * | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Fc領域を含むモノマーポリペプチド及び使用方法 |
| KR20140125803A (ko) * | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| CN105102618B (zh) * | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| EP3027647A4 (en) * | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| LT3027642T (lt) * | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| SG10201913507SA (en) * | 2014-05-02 | 2020-02-27 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| WO2018166461A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| US12054527B2 (en) * | 2018-04-09 | 2024-08-06 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| CN113286812B (zh) * | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| KR20210080460A (ko) * | 2018-10-23 | 2021-06-30 | 드래곤플라이 쎄라퓨틱스, 인크. | 이종이량체성 Fc-융합된 단백질 |
| BR112021021271A2 (pt) * | 2019-04-23 | 2021-12-21 | Lg Chemical Ltd | Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15 |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| CA3161302A1 (en) * | 2019-11-26 | 2021-06-03 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
| CA3171363A1 (en) * | 2019-12-20 | 2021-06-24 | Kisoji Biotechnology Inc. | Polypeptides, protein complexes and method for making same |
| EP4458863A1 (en) * | 2021-12-31 | 2024-11-06 | Sunshine Lake Pharma Co., Ltd. | Fusion protein of glp-1 and gdf15 and use thereof |
-
2022
- 2022-08-23 US US18/682,002 patent/US20240350588A1/en active Pending
- 2022-08-23 WO PCT/CN2022/114096 patent/WO2023025120A1/en not_active Ceased
- 2022-08-23 CN CN202211012820.3A patent/CN115925982A/zh active Pending
- 2022-08-23 US US18/685,702 patent/US20240391971A1/en active Pending
- 2022-08-23 KR KR1020247009488A patent/KR20240049337A/ko active Pending
- 2022-08-23 CN CN202211013315.0A patent/CN115925984A/zh active Pending
- 2022-08-23 US US18/294,397 patent/US20240343770A1/en active Pending
- 2022-08-23 CN CN202211012940.3A patent/CN115925983A/zh active Pending
- 2022-08-23 AU AU2022333099A patent/AU2022333099A1/en active Pending
- 2022-08-23 EP EP22860469.0A patent/EP4393941A4/en active Pending
- 2022-08-23 WO PCT/CN2022/114130 patent/WO2023025123A1/zh not_active Ceased
- 2022-08-23 CA CA3226178A patent/CA3226178A1/en active Pending
- 2022-08-23 EP EP22860466.6A patent/EP4392461A4/en active Pending
- 2022-08-23 WO PCT/CN2022/114143 patent/WO2023025129A1/zh not_active Ceased
- 2022-08-23 JP JP2024512156A patent/JP2024532882A/ja active Pending
- 2022-08-23 EP EP22860475.7A patent/EP4393940A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240350588A1 (en) | 2024-10-24 |
| EP4393941A4 (en) | 2025-10-15 |
| AU2022333099A1 (en) | 2024-02-08 |
| KR20240049337A (ko) | 2024-04-16 |
| CN115925982A (zh) | 2023-04-07 |
| EP4393941A1 (en) | 2024-07-03 |
| WO2023025120A1 (en) | 2023-03-02 |
| JP2024532882A (ja) | 2024-09-10 |
| CN115925983A (zh) | 2023-04-07 |
| CN115925984A (zh) | 2023-04-07 |
| EP4393940A1 (en) | 2024-07-03 |
| WO2023025129A1 (zh) | 2023-03-02 |
| EP4392461A4 (en) | 2025-10-15 |
| EP4393940A4 (en) | 2025-10-15 |
| US20240391971A1 (en) | 2024-11-28 |
| EP4392461A1 (en) | 2024-07-03 |
| WO2023025123A1 (zh) | 2023-03-02 |
| US20240343770A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2697257B1 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
| JP2024020405A (ja) | 神経ペプチドy受容体の調節因子としての抗体結合環状ペプチドチロシンチロシン化合物 | |
| AU2020200329A1 (en) | Stabilization of Fc-containing polypeptides | |
| US8871907B2 (en) | Glycosylated immunoglobulin and immunoadhesin comprising the same | |
| CN108570109A (zh) | 包含免疫球蛋白Fc部分的双靶点融合蛋白 | |
| KR20190026684A (ko) | 유전자 조작 Fc 작제물에 관한 조성물 및 방법 | |
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| US20250179142A1 (en) | Fusion protein of glp-1 and gdf15 and use thereof | |
| US20240343770A1 (en) | Gdf15 fusion proteins and uses thereof | |
| CN116948037A (zh) | 一种新结构长效卵泡刺激素重组蛋白及其制备和应用 | |
| CN114621353A (zh) | 一种重组融合蛋白及其应用 | |
| CA2469724A1 (en) | Mutant glycoproteins | |
| WO2025252023A1 (en) | Modulators for gipr, glp1r and/or gcgr and uses thereof | |
| CN116948036A (zh) | 重组孕马血清促性腺激素及其制备方法和应用 | |
| AU2005209571A1 (en) | Methods and compostions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250630 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250630 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260623 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260623 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260623 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260724 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260724 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260724 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260724 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260724 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260727 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260727 |